New Trends in the Field Triple-agonist therapies approaching weight loss levels previously seen only with bariatric surgery Oral formulations that eliminate the need for injections, improving access and patient preference Monthly or less frequent dosing options to improve adherence Enhanced understanding of how combining different hormonal pathways can optimize weight loss and metabolic health Weight Loss Medications in the Pipeline Researchers are evaluating several promising agents in late-stage clinical trials: Retatrutide : A triple GIP/GLP-1/glucagon receptor agonist that demonstrated weight loss of approximately 24% at 48 weeks on the 12 mg dose
Shared decision-making should weigh the established benefits of semaglutide for diabetes control and weight management against theoretical thyroid risks, particularly in patients with multiple cardiovascular risk factors who stand to benefit substantially from treatment
It depends on individual needs and skin types
You will likely have to pay for the medication out-of-pocket
Lemme may appeal to supplement users looking for something low-effort, but it doesnt match the clinical support or treatment strength these programs provide, and the supplement itself does not rival GLP-1s in weight-loss results
Like, I think its good for you